Mitochondria-localized iridium(III) complexes as chemotherapeutic agents against melanoma

IF 2.4 3区化学 Q2 CHEMISTRY, INORGANIC & NUCLEAR

Polyhedron Pub Date : 2025-04-01 DOI:10.1016/j.poly.2025.117527

Ziyang Liu , Qixuan Zhang , Yixiong Yang , Ruochen Li , Xiyao Liu , Qingyi Lin , Zhanghui Zhu , Zhuohuai Gao , Tao Feng , Tianfang Cheng , Jian Wang , Hui Chao

引用次数: 0

Abstract

Chemotherapy remains the mainstay of cancer treatment. There is a growing propensity to design and develop drugs with structural complexity to enhance therapeutic efficacy. However, complex structures are complicated to prepare and are prone to uncertainties. On the contrary, simplifying structures is a practical approach to clarifying the treatment effect and the success of drug design. Herein, we design three cyclometalated Ir(III) complexes with simple structures that target the mitochondria to induce cell apoptosis. Briefly, the Ir(III) complexes can target mitochondria and cause mitochondrial damage by disrupting mitochondrial membrane potential, which activates the Caspase 3/7-dependent apoptotic pathway and thus inhibits melanoma at cellular. Therefore, constructing simple structural metal complexes offers a promising strategy for treating cancer.

Abstract Image

查看原文本刊更多论文

线粒体定位铱（III）复合物作为黑色素瘤的化疗药物

化疗仍然是癌症治疗的主要手段。人们越来越倾向于设计和开发结构复杂的药物，以提高治疗效果。然而，复杂的结构制备起来很复杂，而且容易产生不确定性。相反，简化结构是明确治疗效果和药物设计成功的实用方法。在此，我们设计了三种结构简单的环金属化Ir（III）复合物，以线粒体为靶点诱导细胞凋亡。简言之，Ir（III）复合物可以靶向线粒体，通过破坏线粒体膜电位导致线粒体损伤，激活Caspase 3/7依赖性凋亡通路，从而在细胞层面抑制黑色素瘤。因此，构建简单结构的金属配合物为治疗癌症提供了一种很有前景的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Polyhedron 化学-晶体学

CiteScore

4.90

自引率

7.70%

发文量

515

审稿时长

2 months

期刊介绍： Polyhedron publishes original, fundamental, experimental and theoretical work of the highest quality in all the major areas of inorganic chemistry. This includes synthetic chemistry, coordination chemistry, organometallic chemistry, bioinorganic chemistry, and solid-state and materials chemistry. Papers should be significant pieces of work, and all new compounds must be appropriately characterized. The inclusion of single-crystal X-ray structural data is strongly encouraged, but papers reporting only the X-ray structure determination of a single compound will usually not be considered. Papers on solid-state or materials chemistry will be expected to have a significant molecular chemistry component (such as the synthesis and characterization of the molecular precursors and/or a systematic study of the use of different precursors or reaction conditions) or demonstrate a cutting-edge application (for example inorganic materials for energy applications). Papers dealing only with stability constants are not considered.